Santhera Pharmaceuticals 

Santhera Pharmaceuticals Holding AG operates as a specialized drug developer that, along with its affiliated entities, focuses on bringing to market therapeutic solutions for uncommon neuromuscular and lung conditions where current treatment options are insufficient. Its operations span the European Union and other global regions. Its most advanced experimental drug, vamorolone, is currently undergoing development to combat Duchenne muscular dystrophy (DMD). The clinical development portfolio also features lonodelestat (known as POL6014), targeting cystic fibrosis and various neutrophilic lung ailments, alongside omigapil, intended for congenital muscular dystrophies. Furthermore, Santhera has granted licensing rights for its approved medication, Raxone (idebenone), used in treating Leber's hereditary optic neuropathy, to partners in territories excluding North America and France. Established in 2004, this company maintains its principal office in Pratteln, Switzerland.